Abramorama has acquired North American theatrical rights to “Shuffle,” the Benjamin Flaherty documentary that captured the Grand Jury Prize for Best Documentary Feature at the 2025 SXSW Film & TV Festival.

The film takes viewers inside the addiction treatment industry, a business valued in the billions. Through three interwoven stories, Flaherty traces how vulnerable patients are steered through programs designed to maximize insurance payouts rather than long-term recovery. The director narrates the film himself, grounding the investigation with his own journey through recovery. Along the way, he enlists insight from an FBI informant, an insurance analyst and the former executive director of a Philadelphia treatment center.

Shot over three years, “Shuffle” has carved out a strong festival run since its SXSW premiere. Regionally, the doc screened at the 2025 Vashon Island Film Festival where Flaherty was among the nominees for Best Director. The film’s momentum has already secured it a spot on the list of documentaries eligible for the 2026 Academy Awards.

Abramorama will partner with Kinema for a slate of event screenings this fall before sending the film into wider release in early 2026. Known for championing socially charged nonfiction titles, the distributor is expected to push “Shuffle” one of the year’s must-see investigative docs.

For Abramorama, the acquisition of “Shuffle” adds another high-profile title to its specialty slate, while for Flaherty, his debut documentary marks a strong outing that could carry “Shuffle” from festival favorite to awards season player.